Creation of the First Tuberculosis Biobank in the UK

Tuberculosis (TB) is currently a global pandemic. The World Health Organization (WHO) estimates that 2 billion people (a third of the worlds population) is infected with Mycobacterium tuberculosis, the bacterium which causes the disease. Fisher BioServices UK is currently collaborating with partners on a global phase III clinical trial to create a biobank of blood, urine and sputum samples taken from TB-positive patients during treatment. These samples can be used in the future to test potential biomarkers of treatment response that may serve as surrogate endpoints for long-term relapse data. Samples have been collected in the Phase III for the evaluation of one of the fourth generation synthetic uoroquinolone antibacterial agent in the treatment of sputum-smear-positive tuberculosis trial. The collection of samples will be pursued from at least another 1000 patients and if researchers are successful in identifying new biomarkers, these efforts could lead to the first new drug approved in the treatment of drug-sensitive TB in 50 years.

To learn more about the objective, methods, and progress of the first tuberculosis biobank in the UK, download our scientific poster below!


Download InfoPoster Here